A new clot-busting drug called tenecteplase can be administered in seconds rather than through an hour-long infusion; studies ...

A new study suggests that the 0.25-mg/kg dose of the thrombolytic tenecteplase (TNK) is just as good at facilitating reperfusion of the blocked artery in patients with ischemic large-vessel stroke ...

Please provide your email address to receive an email when new articles are posted on . A 0.4 mg/kg dose of tenecteplase administered before endovascular thrombectomy in patients with large vessel ...

Giving very late thrombolysis to patients with large-vessel occlusion small core strokes did not show a significant benefit in the TIMELESS trial. However, there were some encouraging trends, and ...

For patients with acute ischemic stroke (AIS), tenecteplase (TNK) has improved functional outcome and reduced disability and similar safety to alteplase (tissue plasminogen activator [TPA]), according ...

Stroke survivors were more likely to have little or no disability after 90 days if a clot was removed from a large brain artery followed by the injection of the clot-dissolving medication tenecteplase ...

Please provide your email address to receive an email when new articles are posted on . Among patients with acute ischemic stroke who were selected for thrombectomy, treatment with tenecteplase, ...